Venus Concept Inc.

Equities

VERO

US92332W2044

Advanced Medical Equipment & Technology

Delayed Nasdaq 01:22:49 2024-04-19 pm EDT 5-day change 1st Jan Change
0.86 USD +2.38% Intraday chart for Venus Concept Inc. +26.92% -27.12%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Venus Concept Inc. Announces Israeli Regulatory Approval for Venus Bliss MAX CI
Transcript : Venus Concept Inc., Q4 2023 Earnings Call, Apr 01, 2024
Venus Concept Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Venus Concept Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (VERO) VENUS CONCEPT Posts Q4 Revenue $18.1M MT
Venus Concept Inc. Provides Earning Guidance for the Three Months Ended March 31, 2024 CI
Venus Concept Continues Listing on Nasdaq, Gets May Deadline to Meet Equity Requirement MT
Certain Options of Venus Concept Inc. are subject to a Lock-Up Agreement Ending on 13-MAR-2024. CI
Venus Concept Inc. announced that it has received CAD 1.095782 million in funding CI
Venus Concept Inc. announced that it expects to receive CAD 1.095782 million in funding CI
Madryn Asset Provides Information to the Shareholders CI
Venus Concept Announces Review of Strategic Alternatives CI
Venus Concept Inc. announced that it has received CAD 2 million in funding from Essex Woodlands Management, Inc. and another investor CI
Venus Concept Inc. Announces New International Distributors in the United Kingdom and India to Continue Global Growth CI
Transcript : Venus Concept Inc., Q3 2023 Earnings Call, Nov 14, 2023
Venus Concept Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (VERO) VENUS CONCEPT Reports Q3 Revenue $17.6M, vs. Street Est of $17.5M MT
Earnings Flash (VERO) VENUS CONCEPT Posts Q3 Revenue $17.6M, vs. Street Est of $17.5M MT
Venus Concept Inc. Provides Earnings Guidance for the Twelve Months Ending December 31, 2023 CI
Venus Concept Inc. Launches Venus Versa Pro, its New Multi-Application Platform for Face and Body Treatments CI
Madryn Asset Management Engages in Discussions with Venus Concept CI
Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer, Effective October 16, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
BTIG Downgrades Venus Concept to Neutral From Buy MT
Venus Concept Signs Debt Restructuring Agreement, Cuts 2023 Revenue Outlook MT
Chart Venus Concept Inc.
More charts
Venus Concept Inc. is a global medical aesthetic technology company. The Company has a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches in over 60 countries and 14 direct markets. The Company's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Its hair restoration systems include NeoGraft and the ARTAS iX Robotic Hair Restoration system. The Company's systems are designed on flexible platforms that enable it to expand beyond the aesthetic industry's traditional markets of dermatology and plastic surgery, and into non-traditional markets, including family and general practitioners and aesthetic medical spas. The Company's hair loss treatment solutions include the ARTAS Solution and the NeoGraft Solution.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.84
Average target price
-
Consensus
  1. Stock Market
  2. Equities
  3. VERO Stock
  4. News Venus Concept Inc.
  5. Stifel Nicolaus Adjusts Venus Concept Price Target to $1 From $2, Maintains Hold Rating